Abiraterone acetate is a Small Molecule owned by Johnson & Johnson, and is involved in 110 clinical trials, of which 85 were completed, and 25 are ongoing.

Abiraterone acetate is converted to abiraterone, an androgen biosynthesis inhibitor that inhibits 17 a-hydroxylase/C17, 20-lyase (CYP17). This enzyme is expressed in testicular, adrenal, and prostatic tumor tissues and is required for androgen biosynthesis. CYP17 converts pregnenolone and progesterone to their 17a-hydroxy derivatives by 17a-hydroxylase activity and the subsequent formation of dehydroepiandrosterone (DHEA) and androstenedione, respectively, by C17, 20 lyase activity. Inhibition of CYP17 by abiraterone can also result in increased mineralocorticoid production by the adrenals.

The revenue for Abiraterone acetate is expected to reach a total of $6bn through 2038. This change impacts the valuation of this asset and is an important factor to understand the current value of the drug in a clinical process. GlobalData uses proprietary data and analytics to provide a complete picture of this assessment in their Abiraterone acetate NPV Report.

Abiraterone acetate was originated by Institute of Cancer Research and is currently owned by Johnson & Johnson.

Abiraterone acetate Overview

Abiraterone acetate (Zytiga) is an antineoplastic agent. It is formulated as tablets and film coated tablets for oral route of administration. Zytiga is indicated in combination with prednisone for the treatment of metastatic prostate cancer (castration-resistant prostate cancer) in patients who are asymptomatic or mildly symptomatic after failure of androgen deprivation therapy and in patients who have received prior chemotherapy containing docetaxel after failure of androgen deprivation therapy and in combination with prednisone for the treatment of patients with metastatic high-risk castration-sensitive prostate cancer.

Abiraterone acetate is under development for metastatic breast cancer, HER2 negative breast cancer and salivary gland cancer.

It was also under development for the treatment of epithelial ovarian (including fallopian tube and primary peritoneal) cancer.

Johnson & Johnson Overview

Johnson & Johnson (J&J) researches, develops, manufactures, and sells pharmaceutical products, medical devices, and consumer products. The company provides pharmaceuticals for immune diseases, cancer, neurological disorders, infectious, cardiovascular and metabolic diseases; consumer products in oral care, baby care, beauty, over-the-counter (OTC) medicines, women’s health and wound care categories; and medical devices for use in the cardiovascular, orthopaedic, general surgery and vision care fields. J&J distributes pharmaceutical and medical products to retailers, wholesalers, health care professionals and hospitals; and offers consumer products through retail outlets and distributors. The company offers its products in the US; Europe; Asia-Pacific and Africa; and Western Hemisphere (excluding the US). J&J is headquartered in New Brunswick, New Jersey, the US.

The company reported revenues of (US Dollars) US$93,775 million for the fiscal year ended January 2021 (FY2021), an increase of 13.6% over FY2020. In FY2021, the company’s operating margin was 24.3%, compared to an operating margin of 20% in FY2020. In FY2021, the company recorded a net margin of 22.3%, compared to a net margin of 17.8% in FY2020. The company reported revenues of US$23,791 million for the third quarter ended October 2022, a decrease of 1% over the previous quarter.

Quick View – Abiraterone acetate

Report Segments
  • Innovator (NME)
Drug Name
  • Abiraterone acetate
Administration Pathway
  • Oral
Therapeutic Areas
  • Oncology
Key Companies
Highest Development Stage
  • Marketed

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

To create this model, GlobalData takes into account factors including patent law, known and projected regulatory approval processes, cash flows, potential applicable patients, drug margins, company expenses, and pricing estimates. Combining these data points with GlobalData’s world class analysis creates high value models that companies can use to help in evaluation processes for each drug or company.

The rNPV method integrates the probability of a drug reaching a clinical stage into the cash flow at that time, which provides a more accurate rNPV, as it considers the probability that the drug never makes it through the clinical pathway to commercialization. GlobalData’s rNPV model uses proprietary likelihood of approval (LoA)and phase transition success rate(PTSR) data for the indication in the highest development stage, which can be found on GlobalData’s Pharmaceutical Intelligence Center.